Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto.
Breast cancer
Central nervous system metastases
First site of metastatic disease
Journal
Breast cancer research : BCR
ISSN: 1465-542X
Titre abrégé: Breast Cancer Res
Pays: England
ID NLM: 100927353
Informations de publication
Date de publication:
10 05 2019
10 05 2019
Historique:
received:
22
08
2018
accepted:
17
04
2019
entrez:
12
5
2019
pubmed:
12
5
2019
medline:
10
1
2020
Statut:
epublish
Résumé
The incidence of central nervous system (CNS) metastases in breast cancer patients is rising and has become a major clinical challenge. Only few data are published concerning risk factors for the development of CNS metastases as a first site of metastatic disease in breast cancer patients. Moreover, the incidence of CNS metastases after modern neoadjuvant treatment is not clear. We analyzed clinical factors associated with the occurrence of CNS metastases as the first site of metastatic disease in breast cancer patients after neoadjuvant treatment in the trials GeparQuinto and GeparSixto (n = 3160) where patients received targeted treatment in addition to taxane and anthracycline-based chemotherapy. After a median follow-up of 61 months, 108 (3%) of a total of 3160 patients developed CNS metastases as the first site of recurrence and 411 (13%) patients had metastatic disease outside the CNS. Thirty-six patients (1%) developed both CNS metastases and other distant metastases as the first site of metastatic disease. Regarding subtypes of the primary tumor, 1% of luminal A-like (11/954), 2% of luminal B-like (7/381), 4% of HER2-positive (34/809), and 6% of triple-negative patients (56/1008) developed CNS metastases as the first site of metastatic disease. In multivariate analysis, risk factors for the development of CNS metastases were larger tumor size (cT3-4; HR 1.63, 95% CI 1.08-2.46, p = 0.021), node-positive disease (HR 2.57, 95% CI 1.64-4.04, p < 0.001), no pCR after neoadjuvant chemotherapy (HR 2.29, 95% CI 1.32-3.97, p = 0.003), and HER2-positive (HR 3.80, 95% CI 1.89-7.64, p < 0.001) or triple-negative subtype (HR 6.38, 95% CI 3.28-12.44, p < 0.001). Especially patients with HER2-positive and triple-negative tumors are at risk of developing CNS metastases despite effective systemic treatment. A better understanding of the underlying mechanisms is required in order to develop potential preventive strategies.
Sections du résumé
BACKGROUND
The incidence of central nervous system (CNS) metastases in breast cancer patients is rising and has become a major clinical challenge. Only few data are published concerning risk factors for the development of CNS metastases as a first site of metastatic disease in breast cancer patients. Moreover, the incidence of CNS metastases after modern neoadjuvant treatment is not clear.
METHODS
We analyzed clinical factors associated with the occurrence of CNS metastases as the first site of metastatic disease in breast cancer patients after neoadjuvant treatment in the trials GeparQuinto and GeparSixto (n = 3160) where patients received targeted treatment in addition to taxane and anthracycline-based chemotherapy.
RESULTS
After a median follow-up of 61 months, 108 (3%) of a total of 3160 patients developed CNS metastases as the first site of recurrence and 411 (13%) patients had metastatic disease outside the CNS. Thirty-six patients (1%) developed both CNS metastases and other distant metastases as the first site of metastatic disease. Regarding subtypes of the primary tumor, 1% of luminal A-like (11/954), 2% of luminal B-like (7/381), 4% of HER2-positive (34/809), and 6% of triple-negative patients (56/1008) developed CNS metastases as the first site of metastatic disease. In multivariate analysis, risk factors for the development of CNS metastases were larger tumor size (cT3-4; HR 1.63, 95% CI 1.08-2.46, p = 0.021), node-positive disease (HR 2.57, 95% CI 1.64-4.04, p < 0.001), no pCR after neoadjuvant chemotherapy (HR 2.29, 95% CI 1.32-3.97, p = 0.003), and HER2-positive (HR 3.80, 95% CI 1.89-7.64, p < 0.001) or triple-negative subtype (HR 6.38, 95% CI 3.28-12.44, p < 0.001).
CONCLUSIONS
Especially patients with HER2-positive and triple-negative tumors are at risk of developing CNS metastases despite effective systemic treatment. A better understanding of the underlying mechanisms is required in order to develop potential preventive strategies.
Identifiants
pubmed: 31077239
doi: 10.1186/s13058-019-1144-x
pii: 10.1186/s13058-019-1144-x
pmc: PMC6509843
doi:
Banques de données
EudraCT
['2006-005834-19']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
60Références
Breast Cancer Res Treat. 2014 Aug;147(1):103-12
pubmed: 25106661
Lancet Oncol. 2012 Feb;13(2):135-44
pubmed: 22257523
Breast J. 2008 May-Jun;14(3):245-9
pubmed: 18433402
J Clin Oncol. 2013 Aug 10;31(23):2963-9
pubmed: 23835712
Breast Cancer Res. 2011 Sep 13;13(5):R87
pubmed: 21914172
Cancer Res. 2008 May 1;68(9):3108-14
pubmed: 18451135
Lancet Oncol. 2014 Jun;15(7):747-56
pubmed: 24794243
Neurosurg Rev. 2013 Jul;36(3):377-82
pubmed: 23262837
J Clin Oncol. 2010 Jul 10;28(20):3271-7
pubmed: 20498394
Ann Surg. 2017 Oct;266(4):667-676
pubmed: 28657941
Cancer. 2012 Nov 15;118(22):5463-72
pubmed: 22544643
Cancer. 2012 Oct 1;118(19):4652-9
pubmed: 22359359
Eur J Cancer. 2013 Jul;49(10):2284-93
pubmed: 23541564
Breast Cancer Res Treat. 2012 Nov;136(1):153-60
pubmed: 22968656
Ann Oncol. 2017 Mar 1;28(3):497-504
pubmed: 27831502
Ann Oncol. 2014 Dec;25(12):2363-72
pubmed: 25223482
Ann Oncol. 2010 May;21(5):942-8
pubmed: 19840953
JAMA Oncol. 2017 Aug 1;3(8):1069-1077
pubmed: 28301662
Breast Cancer Res. 2012 Oct 01;14(5):R129
pubmed: 23025714
Am J Clin Pathol. 2015 Apr;143(4):471-8
pubmed: 25779997
Cancer. 2004 Oct 15;101(8):1760-6
pubmed: 15386311